insights_auto
Outlook: 37.5% bullish·16.7% bearish
Go to analysischevron_right
BNTX:NASDAQ
BioNTech SE - ADR
$96.06
arrow_downward
-2.64%(-2.60) 1D
$96.06
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 18, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$98.81
High
$99.25
Low
$95.71
Mkt. cap
24.13B
Avg. vol.
1.45M
Volume
1.20M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.70
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
Open
$98.81
High
$99.25
Low
$95.71
Mkt. cap
24.13B
Avg. vol.
1.45M
Volume
1.20M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.70
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
AD HOC NEWS
·
5 hours ago
BioNTech SE stock dips as CEO share sales and trial update reshape risk view
Simply Wall Street
·
2 days ago
Did Survival Trial Win Just Shift BioNTech (BNTX) Investment Narrative?
24/7 Wall St.
·
3 days ago
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
CarePlus VietNam
·
1 month ago
BioNTech (BNTX) Slides 2.44% as Selling Pressure Persists Near Key Support Zone - Percent Below MA
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR